Introduction {#s1}
============

According to the International Diabetes Federation (IDF) survey in 2017, approximately 451 million people aged 18 to 99 years worldwide are suffering from diabetes mellitus, and the number was expected to increase to 693 million by year 2045 ([@B3]). China Kadoorie Biobank (CKB) data from 170,287 participants showed that the estimated standardized prevalence of total diagnosed and undiagnosed diabetes in urban and rural China reached 10.9% in 2013 and that of pre-diabetic patients was 35.7% ([@B30]). In reality, diabetes mellitus and its complications seriously deteriorate patients' quality of life ([@B28]).

Diabetic kidney disease (DKD), a well-established microvascular complications of diabetes mellitus, is also the most frequent primary cause of end-stage renal disease (ESRD) ([@B11]). In 2014, the American Diabetes Association (ADA) and the National Kidney Foundation (NKF) defined DKD as a chronic kidney disease (CKD) caused by diabetes mellitus, which was characterized by glomerular basement membrane thickening, mesangial expansion, nodular sclerosis, and finally, advanced diabetic glomerulosclerosis ([@B27]). DKD accounted in more than 40% of ESRD ([@B23]; [@B32]).

The all-age DKD mortality rates in China increased by 33.3% from 1990 to 2016 ([@B16]). Accordingly, the Global Burden of Disease (GBD) reported that deaths from DKD all over the world also significantly grew up with an increase percentage of 40.73% from 2007 to 2017 ([@B4]). Therefore, the growing prevalence and mortality due to DKD constitute a huge health and social economic burden and have become a serious public health problem in China and all over the world ([@B5]).

DKD is a complex disease with multiple etiologies and pathogenesis, including genetic determinants, glucose/lipid metabolism disorders, glomerular hemodynamic changes, and abnormal expression of cytokines ([@B13]; [@B17]; [@B12]). Identification of genetic markers linked to DKD could provide deep insights into the underlying biological processes of the renal dysfunction. Previous studies suggested that variants in TGF-β/Smad classic pathway and Wnt/β-catenin signaling pathway were associated with DKD ([@B22]; [@B31]).

The *ACTB* gene encodes an abundant cytoskeletal housekeeping protein β-actin, which is ubiquitous in eukaryotic cells ([@B20]). Recently, a study suggests that a critically reduced amount of β-actin alters cell function and gene expression to the detriment of brain, heart, and kidney development ([@B6]). *ACTB* loss-of-function mutations result in a pleiotropic developmental disorder, including unilateral renal agenesis, pelvic kidney, and kidney cysts, whereas there are few reports about the effect of the common variants at *ACTB* on the renal function. Although five genomewide association studies (GWAS) of DKD identified several susceptible loci ([@B10]; [@B15]; [@B8]; [@B29]; [@B1]; [@B7]), no near loci linked to *ACTB* were observed as well as the data from GWAS of the National Human Genome Research Institute (<https://research.nhgri.nih.gov/>).

This study aimed to evaluate the association between three tagging single-nucleotide polymorphisms (tagSNPs) in the *ACTB* gene and DKD in a Han Chinese cohort of T2DM patients. The findings would provide a better understanding of the genetic susceptibility of *ACTB* in DKD.

Patients and Methods {#s2}
====================

Study Participants {#s2_1}
------------------

Subjects in this analysis were selected from the project of "Comprehensive Research on the Prevention and Control of the Diabetes (CRPCD)," which has been previously described in detail ([@B18]; [@B26]). According to the criteria proposed by the ADA in 2010 ([@B2]), 19,992 subjects with type 2 diabetes mellitus (T2DM) were defined from all 20,340 participants. In the current study, we constructed a case-control study in T2DM subjects with equal DKD cases and controls. Referring to the recommendations released by NKF in 2007 ([@B11]), a total of 3,443 T2DM patients who met one of the following three criteria would be selected as DKD cases: 1) eGFR less than 60 ml·min^−1^·1.73 m^−2^ (n = 2,193); 2) self-reported kidney disease (n = 810); 3) concomitant microvascular disease (mainly diabetic retinopathy) accompanied by CKD stage 2 (eGFR) less than 90 ml·min^−1^·1.73 m^−2^) (n = 1,663). Meanwhile, subjects with the following characteristics were excluded: 1) time interval between T2DM and DKD less than 2 years (n = 94); 2) non-DKD in mentioned self-reported kidney disease (n = 185); 3) diabetes mellitus duration less than 5 years (n = 1,281). Thus, 1,883 DKD cases could be included. We used propensity score matching (PSM) to match a non-DKD control, by age (2 years as an interval), for every case. Finally, 1,510 pairs were involved in this study. Informed consent was obtained from all participants and approved by the Research Ethics Committee of Jiangsu Provincial Center for Disease Control and Prevention and Nanjing Medical University.

Questionnaire Survey and Anthropometric Measurements {#s2_2}
----------------------------------------------------

All staff were uniformly trained and qualified in a standardized manner. Individuals accepted the survey by a questionnaire addressing their demographic characteristics, smoking, drinking, and self-reported chronic disease history. Anthropometric measurements including height, weight, waistline, and hipline were measured with light clothing. Body mass index (BMI) was then calculated as weight (kg)/height squared (m^2^).

Definition of Drinking and Smoking {#s2_3}
----------------------------------

Drinking was defined as at least one alcoholic drink per month. Subjects who have ever smoked 100 cigarettes in the past were considered as smokers.

SNP Selection {#s2_4}
-------------

The *ACTB* gene maps to the chromosome 7p22.1 (Gene ID: 60; Locus NC_000007.14) and spans 3.4 kbp and consists of six exons. We searched the SNPs from the upstream 5 kb to the downstream 2 kb and selected tagSNPs through the database of the Chinese Han population in Beijing (CHB) and China of the International Hap MAP Project (HapMap Data Rel 24/phase II Nov08, on NCBI B36 assembly, dbSNPb126). All tagSNPs were included with a minor allele frequency (MAF) ≥ 0.05 and the criterion of linkage disequilibrium (LD) *r^2^* ≥0.8. Furthermore, a functional candidate strategy was also applied to select potential functional SNPs on the bioinformatics effect prediction website (SNPINFO, <https://snpinfo.niehs.nih.gov/>). Finally, three tagSNPs of *ACTB* gene, rs852423 (A \> G), rs852426 (T \> C), and rs2966449 (T \> C), were selected and genotyped in this study. Detailed biological information was summarized in [**Table S1**](#SM1){ref-type="supplementary-material"}.

Blood Samples Collecting and Genotyping {#s2_5}
---------------------------------------

After an overnight fasting, blood samples were collected in vacuum anticoagulation tubes with ethylenediamine tetraacetic acid dipotassium salt (EDTA-K2)-containing for genotyping. DNA was extracted from the frozen whole blood by a protein precipitation method (Eaglink Cat EGEN2024, NANJING YININGFUSHENG Biotech. Co., Ltd. Nanjing, China) and stored at −20°C. The concentration and the purity of each DNA sample were determined using the NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA). Amplifications of three SNPs were performed using a polymerase chain reaction (PCR)-TaqMan MGB probe array in the GeneAmp^®^ PCR system 9700 thermal cycler (Applied Biosystems, USA). The results were determined on the platform of 7900HT real-time PCR System (Applied Biosystems, Foster City, CA) with a Sequence Detection System (SDS) 2.3 software. To test the genetic effect of SNP, the code of wild types (WT) was 0 (reference), heterozygous types (HT) was 1, and the mutant types (MT) was 2 in additive model. Similar principle was employed in the dominant and recessive models. The successful call rates of SNPs genotyping were 100%. The genotype results were validated by Sanger sequencing, and the consistence was 100% ([**Supplementary Materials**](#SM1){ref-type="supplementary-material"}).

Statistical Analysis {#s2_6}
--------------------

EpiData 3.0 software (The EpiData Association, Odense, Denmark) was performed for duplicate entry, and consistency check was also available. Quantitative variables were expressed as the mean ± standard deviation (SD), and the categorical variables were presented by their counts and proportions. A Fisher's exact test was used to estimate whether the genotype frequencies in controls met the Hardy--Weinberg equilibrium (HWE). Chi-square (χ^2^) test was performed to display the frequencies and distributions of alleles. Binary logistic regression was applied to calculate the odds ratio (OR) and corresponding 95% confidence interval (CI) with adjustment for covariates, and evaluate the genetic effects of different models. All above statistical analyses were conducted on SPSS version 17.0 (SPSS, Inc, Chicago, IL). Stata SE version 12.0 (StataCorp LP, College Station, TX) was used to estimate heterogeneity between groups. Statistical significance was set at 0.05 (*P* ≤ 0.05).

Results {#s3}
=======

Demographic and Clinical Characteristics of DKD Cases and Controls {#s3_1}
------------------------------------------------------------------

[**Table 1**](#T1){ref-type="table"} shows the detailed demographic characteristics of included 1,510 couple individuals. The age (mean ± SD) of 69.87 ± 8.61 years in DKD case group was definitely comparable with that of 69.50 ± 8.74 years in control group (*P* = 0.190). BMI and the proportions of smokers and drinkers in case and control groups were also evenly matched. Nevertheless, the percentage of female in case group was slightly higher than that in the comparison group. Subjects in DKD group had higher levels of systolic pressure (SBP), diastolic pressure (DBP), triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), glucose (GLU), and shorter diabetic duration while lower mean high-density lipoprotein cholesterol (HDL-C) and eGFR than controls (all *P* values \<0.05).

###### 

Demographic and clinical characteristics of DKD cases and controls.

  -----------------------------------------------------------------------------------------------
  Characteristics                Group     Case\            Control\         *t*/χ^2^   *P*
                                           *n* = 1,510      *n* = 1,510                 
  ------------------------------ --------- ---------------- ---------------- ---------- ---------
  Age (year)                               69.87 ± 8.61     69.50 ± 8.74     1.186      0.190

  Gender (%)                     Male      543 (35.96%)     606 (40.13%)     7.576      0.018

                                 Female    967 (64.04%)     904 (59.87%)                

  SB*P* (mm Hg)                            153.78 ± 22.49   150.98 ± 19.98   3.603      \<0.001

  DB*P* (mm Hg)                            79.47 ± 11.9     79.13 ± 10.4     0.820      \<0.001

  BMI (kg/m^2^)                            25.02 ± 3.45     24.93 ± 3.52     0.661      0.258

  TC (mmol/L)                              5.41 ± 1.64      5.22 ± 1.12      3.788      \<0.001

  TG (mmol/L)                              2.13 ± 1.64      1.86 ± 1.54      4.570      0.002

  HDL-C (mmol/L)                           1.50 ± 0.5       1.51 ± 0.4       0.299      \<0.001

  LDL-C (mmol/L)                           3.26 ± 1.24      3.15 ± 0.92      2.953      \<0.001

  GLU (mmol/L)                             9.68 ± 4.25      9.24 ± 3.05      3.222      \<0.001

  eGFR (ml·min^−1^·1.73 m^−2^)             58.69 ± 18.52    83.41 ± 13.44    41.986     \<0.001

  Smoking (%)                    Yes       396 (26.23%)     404 (26.75%)     0.109      0.741

                                 No        1114 (73.77%)    1106 (73.25%)               

  Drinking (%)                   Yes       257 (17.02%)     306 (20.26%)     5.247      0.073

                                 No        1247 (82.58%)    1198 (79.34%)               

                                 Unknown   6 (0.40%)        6 (0.40%)                   
  -----------------------------------------------------------------------------------------------

SBP, systolic blood pressure; DBP, diastolic blood pressure; BMI, body mass index; TC, total cholesterol; TG, triglyceride; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; GLU, glucose; eGFR, estimated glomerular filtration rate.

Association Analysis of the *ACTB* Polymorphisms with DKD {#s3_2}
---------------------------------------------------------

In this study, the genotype distributions of three tagSNPs exactly followed HWE in the control population (all *P* values \> 0.05). We observed that there was difference of rs852423 genotypes between DKD cases and controls, after the adjustment for age, gender, smoking, drinking, BMI, diabetic duration, TG, TC, HDL-C, and LDL-C and the borderline *P* values were 0.046, 0.048, and 0.287 for additive, dominant, and recessive models, respectively ([**Table 2**](#T2){ref-type="table"}). rs852426 T \> C variation presented a remarkable higher risk of DKD in the whole study population, the adjusted OR \[95% confidence interval (CI)\] of additive model was 1.217 (1.079--1.373) with a *P* value of 0.001. After Bonferonni correction (*P*×3), the association still remains statistically significant (*P* = 0.003). The association of rs2966449 (T \> C) with DKD was also significant, and the adjusted OR (95% CI) of additive model was 1.151 (1.025--1.293) with a *P* value of 0.018. When rs852426 and rs2966449 entered the logistic regression model at the same time, the association of rs852426 still remained statistically significant (*P* = 0.016), whereas rs2966449 did not (*P* = 0.202).

###### 

Association analysis of SNPs of the *ACTB* gene with DKD.

  SNP         Group         WT/HT/MT               Genotype OR (95% CI) *P* value[^a^](#fnT2_1){ref-type="table-fn"}   Allele gene                                                      
  ----------- ------------- ---------------------- ------------------------------------------------------------------- ---------------------- ---------- ---------------------- ------- --
  rs852423                  AA/AG/GG                                                                                                                     A/G                            
  Case        716/648/146   1.12 (1.002--1.253)    1.157 (1.001--1.336)                                                1.147 (0.891--1.478)   2080/940   1.115 (0.999--1.245)   0.960   
  Control     765/619/126   *P* = 0.046            *P* = 0.048                                                         *P* = 0.287            2149/871   *P* = 0.053                    
  rs852426                  TT/TC/CC                                                                                                                     T/C                            
  Case        890/518/102   1.217 (1.079--1.373)   1.226 (1.057--1.422)                                                1.522 (1.108--2.089)   2298/722   1.219 (1.079--1.376)   0.300   
  Control     961/479/70    *P* = 0.001            *P* = 0.007                                                         *P* = 0.009            2401/619   *P* = 0.001                    
  rs2966449                 TT/TC/CC                                                                                                                     T/C                            
  Case        810/589/111   1.151 (1.025--1.293)   1.201 (1.039--1.389)                                                1.151 (0.865--1.533)   2289/811   1.107 (0.987--1.243)   0.307   
  Control     874/540/96    *P* = 0.018            *P* = 0.013                                                         *P* = 0.334            2288/732   *P* = 0.083                    

WT, wild type; HT, heterozygote; MT, mutant type.

Adjusted for age, gender, smoking, drinking, BMI and diabetic duration, TG, TC, HDL-C and LDL-C.

P value of χ^2^ text for comparison of allele frequencies between case and control groups.

P value of Fisher's exact two-sided chi-squared test for Hardy--Weinberg equilibrium.

Stratified Analyses by Age, Gender, Smoking, Drinking, and DM Duration {#s3_3}
----------------------------------------------------------------------

The ORs (95% CI) of rs852426 (TC + CC vs. TT) for DKD in 70 years or younger and older than 70 years populations were 1.058 (0.857--1.306) and 1.443 (1.168--1.782) with *P* values of 0.601 and 0.001, respectively. Remarkably, there was significant heterogeneity of the association between the two groups with *P* of 0.047 ([**Table 3**](#T3){ref-type="table"}).

###### 

Stratified analysis of the *ACTB* gene with DKD by age.

  SNP          Age         Group         WT/HT/MT               Genotype OR (95% CI)[^a^](#fnT3_1){ref-type="table-fn"}                                                                                             
  ------------ ----------- ------------- ---------------------- --------------------------------------------------------- ---------------------- ---------------------- -------------------- ---------------------- --------------------
                                         AA/AG/GG                                                                         Heterogeneity test                            Heterogeneity test                          Heterogeneity test
  rs852423     ≤70 years   Case          338/305/70             1.124 (0.959--1.318)                                      *P* = 0.994            1.147 (0.933--1.41)    *P* = 0.912          1.197 (0.837--1.712)   *P* = 0.854
               Control     387/324/66    *P* = 0.150            *P* = 0.193                                               *P* = 0.324                                                                               
  \>70 years   Case        378/343/76    1.125 (0.960--1.317)   1.166 (0.951--1.429)                                      1.140 (0.794--1.637)                                                                      
               Control     378/295/60    *P* = 0.145            *P* = 0.139                                               *P* = 0.477                                                                               
                                         TT/TC/CC                                                                         Heterogeneity test                            Heterogeneity test                          Heterogeneity test
  rs852426     ≤70 years   Case          426/240/47             1.130 (0.949--1.344)                                      *P* = 0.208            1.058 (0.857--1.306)   *P* = 0.047          1.815 (1.132--2.908)   *P* = 0.375
               Control     472/274/31    *P* = 0.170            *P* = 0.601                                               *P* = 0.013                                                                               
  \>70 years   Case        464/278/55    1.323 (1.116--1.568)   1.443 (1.168--1.782)                                      1.332 (0.866--2.048)                                                                      
               Control     489/205/39    *P* = 0.001            *P* = 0.001                                               *P* = 0.192                                                                               
                                         TT/TC/CC                                                                         Heterogeneity test                            Heterogeneity test                          Heterogeneity test
  rs2966449    ≤70 years   Case          386/270/57             1.143 (0.969--1.35)                                       *P* = 0.834            1.121 (0.911--1.380)   *P* = 0.336          1.446 (0.960--2.178)   *P* = 0.190
               Control     4336/296/45   *P* = 0.113            *P* = 0.280                                               *P* = 0.078                                                                               
  \>70 years   Case        424/319/54    1.172 (0.994--1.381)   1.296 (1.055--1.592)                                      0.959 (0.640--1.436)                                                                      
               Control     438/244/51    *P* = 0.059            *P* = 0.013                                               *P* = 0.838                                                                               

Adjusted for gender, smoking, drinking, BMI and diabetic duration, TG, TC, HDL-C and LDL-C.

Also, a significant association of rs852426 and DKD was found in populations of male and female, without smoking and without drinking and with DM duration of 10--20 years ([**Tables S2--5**](#SM1){ref-type="supplementary-material"}). However, no significant heterogeneity was observed between different strata of gender, smoking, drinking, and DM duration.

In addition, the variation of rs2966449 showed significant association with DKD in the populations of older than 70 years, male, without smoking, and without drinking and with DM duration over 20 years ([**Tables S2--5**](#SM1){ref-type="supplementary-material"}). No significant heterogeneity was observed between different strata of gender, smoking, drinking, and DM duration either.

Stratified Analyses by DKD Severity {#s3_4}
-----------------------------------

Further, we divided the DKD cases by its severity with an eGFR of 60 ml·min^−1^·1.73 m^−2^, and the same control group was used to explore the effect of DKD severity on the associations of SNPs and DKD susceptibility ([**Table S6**](#SM1){ref-type="supplementary-material"}). The results indicated that rs852426 was significantly associated with DKD, the ORs (95% CI) and corresponding *P* values were 1.231 (1.047--1.448) (*P* = 0.012) and 1.181 (1.027--1.357) (*P* = 0.019) in additive model.

Analyses for SNPs of the *ACTB* Polymorphisms and eGFR {#s3_5}
------------------------------------------------------

One-way ANOVA revealed that the eGFR levels of the individuals with TT and CC genotypes of rs2966449 were significantly lower than that of TC genotype in DKD cases (*P* = 0.021). Even adjusting for gender, smoking, drinking, BMI, and diabetic duration, the difference still remained (*P* = 0.013), whereas no significant difference of eGFR was found among the genotypes of rs852423 and rs852426 ([**Table 4**](#T4){ref-type="table"}).

###### 

Comparison of eGFR among the genotypes of *ACTB*.

  SNP         DKD Group       eGFR (mean ± SD)   *P*                             
  ----------- --------------- ------------------ --------------- --------------- ------------------------------------------
  rs852423                    AA                 AG              GG              
              Case            57.97 ± 18.26      59.67 ± 18.74   57.83 ± 18.74   0.203
  Control     83.02 ± 13.58   84.17 ± 13.37      82.11 ± 12.83   0.152           
  rs852426                    TT                 TC              CC              
              Case            58.46 ± 18.68      59.06 ± 18.26   58.74 ± 18.57   0.840
  Control     83.01 ± 13.82   84.34 ± 12.78      82.67 ± 12.51   0.189           
  rs2966449                   TT                 TC              CC              
              Case            57.88 ± 18.46      60.26 ± 18.53   56.23 ± 18.47   0.021[^a^](#fnT4_1){ref-type="table-fn"}
  Control     83.02 ± 13.35   84.39 ± 13.62      81.55 ± 13.04   0.065           

The average eGFR levels of the TT and CC genotypes of rs2966449 was significantly lower than that of TC genotype in DKD cases (P \< 0.05 by SNK test).

Discussion {#s4}
==========

Although the GWAS have identified several DN associated loci for European and African populations ([@B19]; [@B21]), only few of them have been validated, and many remained unvalidated ([@B22]). Previous GWAS identified 16 SNPs accounted for only 1.4% of the variability of eGFR ([@B14]). Besides, the functional effect of genetic loci often differs across different ethnicities and populations. More promising candidate genes for DKD remain to be explored.

Because *ACTB* loss-of-function mutations result in renal agenesis and impairment, the study of the common variants at *ACTB* and CKD as well as eGFR would be deserved. In our present study, rs852426 T to C variation, located at the upstream of *ACTB*, is significantly associated with DKD, and the association is particularly significant in the older than 70 years populations with even higher OR (95% CI) of 1.425 (1.155--1.759). The results suggest that aging might promote the impact of rs852426 T to C variation on the development of DKD. We also observed that individuals with TT or CC genotypes of rs2966449 presented lower eGFR level than those with TC genotype, and the result is consistent with the functional characteristics that *ACTB* haploinsufficiency leads to reduced cell proliferation, altered expression of cell-cycle genes, and decreased amounts of nuclear ([@B6]). Previous studies found that DKD occurs incrementally during T2DM in those with long diabetic duration or advanced age ([@B24]). Thus, this study would provide an available genetic marker of precisive prevention from DKD for T2DM patients.

Obviously, the average age in this study, which is near 70 years, has efficient power to find the cut-point of age heterogeneity of the association. The association of rs852426 and DKD also emerged in the subgroup without smoking and drinking and with DM duration of 10--20 years. So, further replication study would warrant large sample to identify the target population of genetic susceptibility to the variation of rs852426. The weak association of rs2966449 and DKD observed in this study is necessary to be replicated by further study.

Previous study demonstrated that β-cytoplasmic actin structures were disorganized, and its expression was downregulated in the epithelial-to-mesenchymal transition (EMT) process in the involvement of fibroblastic phenotype ([@B25]). Ishizawa et al. (2014) reported that Rho kinase was stimulated by its upstream factors in cultured renal tubular cells, triggering EMT to develop to renal fibrosis. In addition, the *ACTB* gene is a downstream gene in the Rho/ROCK pathway. Besides, animal experiment has reported that neonatal rats subjected to partial unilateral ureteral obstruction (PUUO) could produce more actin filaments to control and maintain kidney shape and internal structure ([@B33]). Along with the evidence mentioned above, we therefore speculated with caution that the *ACTB* gene may take a role in the EMT-induced DKD. Bioinformatic analysis indicated that the variations of three tagging SNPs selected in this study as well as other SNPs with MAF \>0.05 in *ACTB* would not cause the structural changes of amino acids; we speculate that the variations of rs852426 and rs2966449 might affect the transcriptional level of *ACTB* by an epigenetic modification way. Further biological functional research would be warranted to explore the potential effect of the variants at *ACTB* on gene transcription, splicing, or mRNA stability as well as the molecular mechanism of DKD.

Our study for the first time explored the associations of the *ACTB* genetic variations with DKD and age- and gender-matched comparison, which was adopted to balance the common confounding factors. Besides, a standard that subjects with T2DM duration more than 5 years were qualified for the study was applied to weaken the discrimination from diabetic duration, which was also guaranteed by statistical adjustments. Moreover, the current subjects were representative because they were selected from about 20,340 T2DM patients from community-based chronic disease management system, distributed in the southern and northern of Jiangsu Province.

There indeed consisted several limitations that should not be ignored. First, we selected candidate SNPs at the *ACTB* with the criterion of MAF ≥ 0.05 and could have missed the rare variants with MAF \<0.05 that may have substantial effects on the occurrence and progress of DKD. Second, case-control design cannot avoid the causal confusion caused by time sequence. Besides, the diabetic duration in this study referred to the time gap from first-diagnosed T2DM to the investigation day, which may overestimate the onset time of DKD. Further follow-up study is warranted.

Conclusion {#s5}
==========

Data from the present study suggest that the *ACTB* genetic variants confer the susceptibility to DKD. SNP rs852426 at this gene is associated with the increased risk of DKD while the association is particularly marked in T2DM patients over 70 years old. SNP rs2966449, however, shows a mild association with DKD and eGFR.
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